Pramipexole is a non-ergot dopamine agonist used primarily in the management of Parkinson’s disease and moderate-to-severe primary restless legs syndrome (RLS). It acts directly on dopamine receptors in the central nervous system, helping compensate for reduced or disrupted dopaminergic signalling associated with these neurological conditions.
Pharmacologically, pramipexole demonstrates high relative specificity and intrinsic activity at the D2 family of dopamine receptors, with particularly strong affinity for the D3 receptor subtype compared with D2 and D4 receptors. Its therapeutic activity in Parkinson’s disease is believed to result largely from stimulation of dopamine receptors within the striatum, an area of the brain involved in regulating movement and motor control.
In Parkinson’s disease, progressive loss of dopamine-producing neurons leads to characteristic motor symptoms including tremor, rigidity, slowed movement and impaired coordination. Dopamine agonists such as pramipexole mimic aspects of dopamine signalling rather than supplying dopamine itself. Pramipexole may be prescribed alone or alongside other Parkinson’s medications depending on disease stage and individual clinical requirements.
Pramipexole is also indicated for moderate-to-severe primary restless legs syndrome, a neurological condition associated with an uncomfortable urge to move the legs, typically becoming more noticeable during periods of rest and at night. Although its exact mechanism in RLS has not been completely established, dopaminergic signalling is believed to play an important role in the condition.
Each tablet provides 1mg of pramipexole, with 100 tablets supplied per pack. Health Canada lists 1mg pramipexole tablet products as prescription medications, with multiple Canadian formulations containing pramipexole dihydrochloride monohydrate.
Pramipexole has important neurological and behavioural safety considerations. Dopamine agonists can cause significant sleepiness or episodes of suddenly falling asleep, hallucinations, dizziness and changes in blood pressure. Some patients may also experience new or increased compulsive behaviours such as gambling, excessive spending, compulsive eating or increased sexual urges.
Treatment should not be stopped abruptly without medical guidance. Health Canada has specifically reviewed dopamine agonist withdrawal syndrome, which can occur following reduction or discontinuation of dopamine agonists including pramipexole. Dose selection and discontinuation should therefore be managed by a qualified healthcare professional.
Pramipexole is a prescription medication and should be used only according to the directions of a healthcare professional.
![PRAMIPEXOLE 1MG X 100 [PARKINSON'S]](https://www.canadasteroiddepot.is/wp-content/uploads/2025/09/PRAMIPEXOLE-1-X-100-600x600.webp)
![ESTRADIOL 2MG X 100 [HORMONE THERAPY]](https://www.canadasteroiddepot.is/wp-content/uploads/2025/10/ESTRADIOL-2-X-100-300x300.webp)
![PRAMIPEXOLE 1MG X 100 [PARKINSON'S]](https://www.canadasteroiddepot.is/wp-content/uploads/2025/09/PRAMIPEXOLE-1-X-100-100x100.webp)